Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

In our large observational cohort, use of tenofovir disoproxil fumarate (n=344) was associated with a greater decline in renal function than was use of alternative nucleoside analogues (n=314). Other associations included a lower CD4 cell count, decreased renal function at baseline, and diabetes. The declines were modest and did not lead to greater rates of discontinuation of therapy.